Cefdinir: Difference between revisions
(Replace manual dosing with dynamic SMW tables (Adult + Pediatric)) |
(Restore original dosing content alongside dynamic SMW tables) |
||
| Line 7: | Line 7: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*600mg/d divided q12-24hrs for 10 days for [[CAP]], chronic [[bronchitis]], acute [[sinusitis]], [[strep pharyngitis]], [[cellulitis]] | |||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Cefdinir]] [[Has Population::Adult]] | {{#ask: [[Has DrugName::Cefdinir]] [[Has Population::Adult]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*14mg/kg/d PO divided q12-24hrs x10 days, max of 600mg/day | |||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Cefdinir]] [[Has Population::Pediatric]] | {{#ask: [[Has DrugName::Cefdinir]] [[Has Population::Pediatric]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
Latest revision as of 02:38, 20 March 2026
General
- Type: 3rd generation cephalosporin
- Dosage Forms: capsule, oral suspension
- Dosage Strengths: capsule: 300mg; oral suspension: 125mg/5mL, 250mg/5mL
- Routes of Administration: PO
- Common Trade Names: Omnicef
Adult Dosing
- 600mg/d divided q12-24hrs for 10 days for CAP, chronic bronchitis, acute sinusitis, strep pharyngitis, cellulitis
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Periorbital cellulitis | 300 mg BID | Outpatient |
| Pyelonephritis | 300mg BID PO x 10-14 days | Outpatient |
Pediatric Dosing
- 14mg/kg/d PO divided q12-24hrs x10 days, max of 600mg/day
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Acute otitis media | 14mg/kg/day BID x7-10 days | Prior Month Treatment |
| Periorbital cellulitis | 14 mg/kg per day, divided every 12 hours, max daily 600 mg | Outpatient |
| Pyelonephritis | 14mg/kg/day PO divided BID x 10 days (max 600mg/day) | Pediatric Outpatient |
Special Populations
- Pregnancy Rating: B
- Lactation: Probably safe
- Renal Dosing
- Adult: CrCl <30, 300mg q24hrs; CrCl <10, 300mg q48hrs; supplement after HD
- Pediatric: CrCl <30, 7mg/kg q24, max 300mg/dose; supplement after HD
- Hepatic dosing not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- Diarrhea
- Bloody stools which are guiac negative and returns to normal color after cessation[1]
Pharmacology
- Half-life: 100 min
- Metabolism: Not appreciably metabolized
- Excretion: Urine (7-25% as unchanged drug)
- Mechanism of Action: Bactericidal, inhibits bacterial cell wall synthesis
Antibiotic Sensitivities[2]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia